Taken together, these studies provide evidence that therapies targeting YAP alter drug resistance in NSCLC and effectively suppress the migration, invasion, and metastasis of human NSCLC in vitro and in vivo. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.